CAMBRIDGE, Mass, May 22, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the SVB Securities Biopharma Company Connect event, taking place virtually May 24th- 25th, 2023. Myeloid management will participate in virtual one-on-one meetings with investors during the event. About Myeloid Therapeutics Myeloid Therapeutics is […]